Mologic
Edit

Mologic

https://mologic.co.uk/
Last activity: 20.07.2021
Active
Categories: BioTechCareDevelopmentDiagnosticsHealthTechLearnManufacturingProductResearchService
In 2003, two quirky scientists vowed to make the world a better place. After learning their trades in some of the world’s biggest scientific organisations, Paul and Mark Davis (father and son team with a striking resemblance to Pinky and the Brain established Mologic to do as much good as possible in healthcare and education. They want to improve patient care and quality of life, and break new ground in exciting fields of research (unlike Pinky and the Brain who wanted to take over the world).
Likes
289
Followers
3.18K
Mentions
28
Location: United Kingdom, England, Thurleigh
Employees: 51-200
Phone: +44 1234 780020
Total raised: $9.39M
Founded date: 2003
Twitter
Facebook
LinkedIn

Investors 1

DateNameWebsite
19.01.2021Foresight ...foresightg...

Funding Rounds 2

DateSeriesAmountInvestors
26.12.2016Grant$4.8M-
27.10.2015-$4.59M-

Mentions in press and media 28

DateTitleDescription
20.07.2021Bill Gates and a consortium of investors are buying UK Covid testing tech startup Mologic for $41 millionWith more than one and a half-year into the fight against the deadly coronavirus, many are wondering, why are Bill Gates, George Soros, and a consortium of investors buying a UK Covid testing tech startup company for $41 million? Do they ex...
19.07.2021IPOs con­tin­ue to bus­tle as three more biotechs pre­pare to make the Nas­daq leapEd­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here. The biotech IPO mar­ket con­tin­ues to charge full-steam ahead, with three more com­pa­nies sub­mit­ting their Nas­...
19.07.2021Soros, Gates back medtech's move in­to a 'so­cial en­ter­prise'; Ag­ing an­ti-re­jec­tion drug earns fresh ap­provalGeorge Soros and Bill Gates are team­ing up to buy out a British di­ag­nos­tics com­pa­ny. The pair and their foun­da­tions will spend about $41 mil­lion to trans­form Mo­log­ic in­to a “So­cial En­ter­prise” aimed at ex­pand­ing ac­cess to...
19.07.2021As­traZeneca earns an­oth­er ap­proval in jam-packed Chi­nese PD-(L)1 mar­ket, this time in late-stage lung can­cerOne of the first en­trants in the PD-(L)1 mar­ket in Chi­na, British drug­mak­er As­traZeneca is now look­ing to ce­ment its ad­van­tage there with an­oth­er ap­proval for check­point in­hibitor Imfinzi. Imfinzi was ap­proved by Chi­na’s NM...
19.07.2021FDA’s do­mes­tic bio­phar­ma in­spec­tions re­turn to nor­mal as agency faces back­log of 8,000+BioNTech is putting some of its new-found wealth from its star mRNA vaccine for Covid-19 to use. The biotech $BNTX, which now weighs in with a behemoth $56 billion market cap, is buying a cell therapy R&D platform plus a manufacturing s...
19.07.2021Mer­ck KGaA for­ti­fies its ‘site of the fu­ture’ with $319M re­search, staff train­ing cen­tersEvery­thing be­gan in 1668, in Darm­stadt, Ger­many — so goes Mer­ck KGaA’s de­scrip­tion of its glob­al head­quar­ters. And the con­glom­er­ate has been clear that it’s not go­ing any­where else, un­veil­ing plans in 2019 to lav­ish $1.18 ...
19.07.2021FDA’s do­mes­tic bio­phar­ma in­spec­tions re­turn to nor­mal as agency faces back­log of 8,000+After losing a whole lot of market confidence in their lead drug, little Cytokinetics is now lining up for a crucial Phase III pivotal challenge for the next cardio drug in the pipeline. And that will put them toe-to-toe against powerhouse ...
19.07.2021PureTech-backed Gele­sis wins biotech's lat­est SPAC deal, plan­ning to bring weight loss prod­uct to up to 150M Amer­i­cansEd­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here. The lat­est PureTech-found­ed biotech is head­ing to the New York Stock Ex­change, and it comes through a new SPAC ...
19.07.2021FDA’s do­mes­tic bio­phar­ma in­spec­tions re­turn to nor­mal as agency faces back­log of 8,000+Merck has crossed the FDA finish line with its next-generation pneumococcal vaccine, succeeding in its efforts to one-up — or rather, two-up — Pfizer’s 13-strain shot, Prevnar 13. But can it compete with Pfizer’s recently approved 20-strain...
19.07.2021FDA’s do­mes­tic bio­phar­ma in­spec­tions re­turn to nor­mal as agency faces back­log of 8,000+For the first time since March 2020, the FDA’s in­spec­tions of US-based bio­phar­ma sites have re­turned to nor­mal, FDA act­ing com­mis­sion­er Janet Wood­cock said Mon­day at a small busi­ness reg­u­la­to­ry event. “I’m pleased to say th...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In